Adverse events: severe complications at day 21 · bullous pemphigoid
Clobetasol propionate cream may leads to lower adverse events: severe complications at day 21 compared with oral prednisone (low certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (dichotomous) · active EoE pediatric patients
1 finding from 1 review
Histological improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (dichotomous) · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes clinical improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).
1 finding from 1 review
Clinical improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement at 4 weeks (dichotomous) · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes histological improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE pediatric patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes endoscopic improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).
1 finding from 1 review
Endoscopic improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
1 finding from 1 review
Eradication of P aeruginosa from the respiratory tract: number of participants testing negative for P aeruginosa at 3 months and remaining free until 15 months · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Mean weight‐for‐age z‐score · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Intravenous ceftazidime with tobramycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with oral ciprofloxacin (high certainty).
1 finding from 1 review